Incyte sec filings
WebApr 6, 2024 · Incyte Corp. – Filings and Transcripts – BamSEC Incyte Corp. Watch NASDAQ: INCY Share price (3/29/23): $71.14 Market cap (3/29/23): $15.9 billion 8 Incyte Corp. Expert Interviews, now on BamSEC. Powered by Tegus. See All INCY Interviews Financials Filter 10-K ended 12/31/22 FY 2024 02/07/23 10-Q ended 09/30/22 Q3 11/01/22 10-Q ended … WebJan 9, 2024 · WILMINGTON, D.E. & KENILWORTH, N.J. – Incyte Corporation (Nasdaq:INCY) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the decision to advance the clinical development program investigating the combination of epacadostat, Incyte’s investigational oral selective IDO1 inhibitor, with …
Incyte sec filings
Did you know?
WebFind the latest SEC Filings data for Incyte Corp. Common Stock (INCY) at Nasdaq.com. WebLilly and Incyte Announce Collaboration for Development and Commercialization of Oral Anti-Inflammatory and Autoimmune Therapies. December 21, 2009 ... Incyte's dependence on its relationship with its collaboration partners, and other risks detailed from time to time in Incyte's filings with the Securities and Exchange Commission, including its ...
WebApr 13, 2024 · China Universal Asset Management Co. Ltd. lifted its stake in Incyte Co. (NASDAQ:INCY – Get Rating) by 8.5% during the 4th quarter, according to the company in … WebFeb 8, 2024 · Incyte Corp (INCY) SEC Filing 10-K Annual Report for the fiscal year ending Friday, December 31, 2024 Home SEC Filings Incyte Corp (INCY) 10-K Annual Report Tue …
WebApr 4, 2024 · Pacer Advisors Inc. decreased its position in Incyte Co. (NASDAQ:INCY - Get Rating) by 92.3% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 666 shares of the biopharmaceutical company's stock after selling 7,945 shares during the quart WebSEC Filings Incyte Corp (INCY) 10-K Annual Report Tue Feb 07 2024 10-Q Quarterly Report May 2024 10-Q Quarterly Report November 2024 10-Q Quarterly Report August 2024 10-Q …
WebApr 12, 2024 · Ballentine Partners LLC acquired a new position in shares of Incyte Co. ( NASDAQ:INCY - Get Rating) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 2,609 shares of the biopharmaceutical company's stock, valued at approximately $210,000. 3 S&P 500 …
WebApr 5, 2024 · INCY traded up $1.14 on Wednesday, hitting $73.79. 266,480 shares of the company's stock were exchanged, compared to its average volume of 1,653,264. The company has a current ratio of 3.54, a quick ratio of 3.50 and a debt-to-equity ratio of 0.01. The stock has a fifty day moving average of $77.16 and a two-hundred day moving … crystal\u0027s childcare llcWebApr 9, 2024 · Dupont Capital Management Corp lifted its position in shares of Incyte Co. (NASDAQ:INCY - Get Rating) by 215.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission.The institutional investor owned 9,032 shares of the biopharmaceutical company's stock after … crystal\\u0027s chickenWebIncyte Corp. SEC filings breakout by MarketWatch. View the INCY U.S. Securities and Exchange Commission reporting information. dynamic human shape in motionWebJan 9, 2024 · All companies, foreign and domestic, are required to file registration statements, periodic reports, and other forms electronically through EDGAR. Anyone can access and download this information for free. Here you'll find links to a complete list of filings available through EDGAR and instructions for searching the EDGAR database. dynamic hvac edmontonWebApr 6, 2024 · INCY Incyte CorporationSEC Filings. $75.51 1.73 ( +2.34%) 4:00 PM 04/06/23. NASDAQ $USD Post-Market: $76.42 +0.91 (+1.21%) 7:34 PM. Summary. Ratings. … dynamic hybrid headphonesWebApr 13, 2024 · The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP Maria E. Pasquale sold 60,024 shares of Incyte stock in a transaction that occurred on Monday, January 30th. The stock was sold at an average price of $84.74, for a total value of $5,086,433.76. crystal\u0027s chickenWebSep 27, 2024 · The companies will share development costs associated with global and U.S. -specific trials for all agreed upon trials at a rate of 55% ( Incyte) and 45% (Syndax), with Incyte responsible for 100% of future development costs for trials that are specific to ex- … dynamic human poses for drawing